Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTIXTO3)

• DTT Name: Staphylococcus Topoisomerase IV (Stap-coc parC) DTT Info
• Gene Name: Stap-coc parC

Molecule-Related Drug & Molecule List

10 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[1]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[2]
Delafloxacin Meglumine	DMVTU5Q	Acute bacterial skin infection	1C41	Approved	[3]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[4]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[2]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[2]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[2]
Moxifloxacin	DMU8V4S	Bacterial infection	1A00-1C4Z	Approved	[2]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[5]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[2]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-492	DMJFD2I	Bacterial infection	1A00-1C4Z	Phase 3	[6]
Nemonaxacin	DMIPNBG	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 3	[7]
Zabofloxacin	DMEY1F3	Pneumonia	CA40	Phase 3	[8]
WCK-2349	DMH6XJG	MRSA infection	1D01.0Y	Phase 2	[9]
WCK-771	DMVQARP	Bacterial infection	1A00-1C4Z	Phase 2	[10]
WCK-1152	DMJQHTN	Respiratory tract inflammation	CA07	Phase 1	[11]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avarofloxacin	DMWA957	Bacterial pneumonia	CA40.0	Discontinued in Phase 2	[12]
DX-619	DMSTA5L	Bacterial infection	1A00-1C4Z	Discontinued in Phase 2	[13]
DK-507k	DME5PXL	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[14]
CBR-2092	DMJAGKY	Bacterial infection	1A00-1C4Z	Terminated	[15]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NSFQ-105	DMSLA8X	Discovery agent	N.A.	Investigative	[16]
Premafloxacin	DMC4W03	Discovery agent	N.A.	Investigative	[17]

References

• [1] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
• [6] Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
• [7] In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9.
• [8] DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
• [9] DOI: 10.1038/ja.2013.86
• [10] Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
• [11] DOI: 10.1093/jac/dki361
• [12] Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
• [13] DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7.
• [14] In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone
• [15] In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23.
• [16] Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5.
• [17] Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7.